Key Highlights
- 15% Growth in Specialty Medicines Sales Driven by Respiratory, Oncology, and HIV Advances
GSK’s Specialty Medicines sales surged to £3.3 billion (+15% CER), underpinning core operating profit growth and demonstrating market confidence in high-impact therapeutic areas. - Robust Pipeline with 5 Major New Product Approvals Expected in 2025
Multiple FDA approvals, including novel vaccines and biologics, support GSK’s future growth, with key late-stage programs targeting cancer, liver disease, MASH, and respiratory conditions. - Disciplined R&D and Strategic Partnerships Accelerate Innovation and Long-Term Outlook
Ongoing investment in Oncology and Respiratory Immunology & Inflammation, plus business development deals, position GSK to sustain leadership amid evolving healthcare demands.
Specialty Medicines Fuel Strong Market Momentum
GSK’s specialty portfolio, notably in Respiratory, Immunology & Inflammation (+10%) and Oncology (+42%), drove sales up 15% year-over-year. HIV treatments remained robust (+12%), reinforcing GSK’s footprint in critical therapeutic areas.
Pipeline Advances Accelerate Breakthrough Therapies
2025 milestones include 3 U.S. product launches (Penmenvy meningitis vaccine, Blujepa antibiotic for uUTIs, Nucala for COPD) plus approvals in multiple regions for Blenrep targeting multiple myeloma. Pivotal Phase III trials are underway for next-generation cancer and respiratory treatments.
Strategic Business Development Expands Growth Horizons
Recent acquisition of efimosfermin targets steatotic liver disease, complemented by collaboration with Hengrui Pharma supporting up to 12 new medicines in respiratory and oncology – underscoring GSK’s commitment to pipeline diversification.
Shareholder Returns and Financial Strength
With a declared dividend of 16p for Q2 and a substantial £822 million share buyback in H1 2025, GSK demonstrates strong capital discipline. Confident guidance for 2025 points to top-end growth ranges across turnover, core operating profit, and EPS, reflecting resilience and strategic execution.
About GSK
GSK is a global biopharmaceutical leader committed to advancing healthcare through innovative medicines, vaccines, and specialty treatments. Focused on improving patient outcomes in respiratory, oncology, immunology, and infectious diseases, GSK invests heavily in R&D and strategic partnerships to deliver breakthrough therapies worldwide.
By